, Tracking Stock Market Picks
Enter Symbol:

up 1,155.84 %

PHARMASSET INC. (VRUS) rated Buy with price target $27 by Lazard Capital

Posted on: Tuesday,  Oct 21, 2008  9:25 AM ET by Lazard Capital

Lazard Capital rated Buy PHARMASSET INC. (NASDAQ: VRUS) on 10/21/2008, when the stock price was $10.91. Since
then, PHARMASSET INC. has gained 1155.85% as of 01/17/2012's recent price of $136.95.
If you would have followed this Lazard Capital's recommendation on VRUS, you would have gained 1155.84% of your investment in 1183 days.

Pharmasset, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of drugs to treat viral infections. It focuses on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV).

Lazard Capital Markets’ research team is broadly recognized for its insight, thoroughness, and objectivity. Our goal is to help our clients make the best-informed decisions by providing timely, thoughtful analysis as well as access to company management teams and industry thought leaders. Our industry-focused analysts strive to identify emerging sector trends as well as bottom-up fundamental issues affecting their stocks under coverage. We add value by conducting extensive primary survey work, hosting proprietary events, cultivating industry contacts, and participating in relevant industry conferences.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/21/2008 9:25 AM Buy
10.91 13.50
as of 8/27/2015
1 Week   
1 Month   
3 Months   
1 YTD up  1,156.02 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy